Benzathine Penicillin G is a formulation of two penicillin G molecules. Benzathine Penicillin G is a treatment used for various bacterial infections such as bejel, diphtheria, rheumatic fever, and also syphilis a sexually transmitted infection caused by the Treponema pallidum bacteria. Benzathine Penicillin G is also used to treat respiratory infections caused due to bacteria and viruses. It functions by inhibiting the growth of bacterial and viral infections in the human body. The key factors responsible for causing bacterial and viral infections are decrease in immunity due to change in lifestyle and having unhygienic food and other which supports the growth of the Benzathine Penicillin G market. According to the Centers for Disease Control and Prevention, December 2015, 21.2 million women of the age group of 14 to 49 years were affected by the bacterial vaginosis infection in the US. Such a high prevalence of bacterial infection can influence the market positively.
However, factors such as allergies and side effects associated with treatments are expected to restrict the market growth during the forecast period.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6541
Segmentation The global Benzathine Penicillin G industry is segmented on the basis of application, mode of injection, and end user. The Benzathine Penicillin G market, by application, is segmented into bacterial infections and sexually transmitted infection (STI) syphilis therapy. Bacterial infections are further segmented into Bejel, diphtheria, and rheumatic fever. On the basis of mode of injection, the market is segmented into intravenous and intramuscular injection. On the basis of end user, the global Benzathine Penicillin G market is segmented into hospitals and clinics, diagnostic centers, ambulatory surgical centers, research centers, and others. Regional Analysis The Americas is the largest in the market owing to the increasing prevalence of rheumatic heart disorders and growing healthcare expenditure. According to the National Meningitis Association December 2014, every year approximately 600 to 1000 people are affected by the meningococcal disease in the US. Such a high incidence rate of meningococcal disease drives the market growth in this region. Europe (UK, Belgium, France, and Netherlands) is expected to be the second largest Benzathine Penicillin G market during the forecast period. The increasing occurrence of sexually infective diseases positively drives the market in this region. According to the European Centre for Disease Prevention and Control, September 2015, it is estimated that every year approximately 146 million cases of sexually transmitted infections are found worldwide. In Europe, 385 000 cases were reported in 2013 which may increase during the forecast period. Thus, the growing cases of sexually transmitted infections facilitate market growth. Asia-Pacific was projected to be the fastest growing region for the global Benzathine Penicillin G market in 2017. The market is expected to witness growth owing to the increasing awareness about the treatment and increasing research and development centers in this region. The Middle East and Africa accounts for the lowest share due to lack of availability of well-trained healthcare professionals and low per capita income. However, the rising number of hospitals and healthcare services in the community are expected to support the market. In the region, some developing countries are rising their investments in research and development which is anticipated to contribute to the growth of the market. Key Players Some of the key players in the global Benzathine Penicillin G market are Abcam plc, Pfizer Inc, Alembic IT Department, ECPlaza Network Inc, Sandoz International GmbH, Merck KGaA, Triveni Interchem Private Limited, CSC Pharmaceuticals, and others.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/benzathine-penicillin-g-market-6541
Comentarios